Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2019
Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of N-Methyl-d-Aspartate Receptor Antagonists on Gamma-Band Activity During Auditory Stimulation Compared With Electro/Magneto-encephalographic Data in Schizophrenia and Early-Stage Psychosis: A Systematic Review and Perspective.Schizophrenia bulletin · 2024Pooled it
- Transcranial alternating current stimulation (tACS): from basic mechanisms towards first applications in psychiatry.European archives of psychiatry and clinical neuroscience · 2021Pooled it
- Effects of NMDA-receptor blockade by ketamine on mentalizing and its neural correlates in humans: a randomized control trial.Scientific reports · 2023Trial
- Effects of troxerutin on schizophrenia-like behaviors and oxidative damage in mice.Current research in physiology · 2026Article
- Ultra-high Field fMRI Reveals Effect of Ketamine on Vocal Processing in Common Marmosets.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025Article
- Resting-state EEG and MEG gamma frequencies in schizophrenia: a systematic review and exploratory power-spectrum metanalysis.Schizophrenia (Heidelberg, Germany) · 2025Review
- Article
- Gamma Oscillations as a Biomarker of Neural Circuit Function in Psychosis: Where Are We, and Where Do We Go from Here?Advances in neurobiology · 2024Review
- Auditory Biomarkers of Neuropsychiatric Disorders in Nonhuman Primates.Advances in neurobiology · 2024Review
- The decoupling of structural and functional connectivity of auditory networks in individuals at clinical high-risk for psychosis.The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry · 2023Article
- Opposite Modulation of the NMDA Receptor by Glycine and S-Ketamine and the Effects on Resting State EEG Gamma Activity: New Insights into the Glutamate Hypothesis of Schizophrenia.International journal of molecular sciences · 2023Article
- The Altered States Database: Psychometric data from a systematic literature review.Scientific data · 2022Article
- Intravenous ketamine for depression: A clinical discussion reconsidering best practices in acute hypertension management.Frontiers in psychiatry · 2022Article
- Test-retest reliability of tone- and 40 Hz train-evoked gamma oscillations in female rats and their sensitivity to low-dose NMDA channel blockade.Psychopharmacology · 2021Article
- Optogenetic manipulation of an ascending arousal system tunes cortical broadband gamma power and reveals functional deficits relevant to schizophrenia.Molecular psychiatry · 2021Article
- Ketamine Alters Functional Gamma and Theta Resting-State Connectivity in Healthy Humans: Implications for Schizophrenia Treatment Targeting the Glutamate System.Frontiers in psychiatry · 2021Article
- Brain-Specific Oxysterols and Risk of Schizophrenia in Clinical High-Risk Subjects and Patients With Schizophrenia.Frontiers in psychiatry · 2021Article
- Neurochemistry of Visual Attention.Frontiers in neuroscience · 2021Review
- Translational neurophysiological biomarkers of N-methyl-d-aspartate receptor dysfunction in serine racemase knockout mice.Biomarkers in neuropsychiatry · 2020Article
- Fronto-Temporal Coupling Dynamics During Spontaneous Activity and Auditory Processing in the BatFrontiers in systems neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Abnormal gamma-band oscillations (GBO) have been frequently associated with the pathophysiology of schizophrenia. GBO are modulated by glutamate, a neurotransmitter, which is continuously discussed to shape the complex symptom spectrum in schizophrenia. The current study examined the effects of ketamine, a glutamate N-methyl-D-aspartate receptor (NMDAR) antagonist, on the auditory-evoked gamma-band response (aeGBR) and psychopathological outcomes in healthy volunteers to investigate neuronal mechanisms of psychotic behavior. In a placebo-controlled, randomized crossover design, the aeGBR power, phase-locking factor (PLF) during a choice reaction task, the Positive and Negative Syndrome Scale (PANSS) and the Altered State of Consciousness (5D-ASC) Rating Scale were assessed in 25 healthy subjects. Ketamine was applied in a subanaesthetic dose. Low-resolution brain electromagnetic tomography was used for EEG source localization. Significant reductions of the aeGBR power and PLF were identified under ketamine administration compared to placebo (p < 0.01). Source-space analysis of aeGBR generators revealed significantly reduced current source density (CSD) within the anterior cingulate cortex during ketamine administration. Ketamine induced an increase in all PANSS (p < 0.001) as well as 5D-ASC scores (p < 0.01) and increased response times (p < 0.001) and error rates (p < 0.01). Only negative symptoms were significantly associated with an aeGBR power decrease (p = 0.033) as revealed by multiple linear regression. These findings argue for a substantial role of the glutamate system in the mediation of dysfunctional gamma band responses and negative symptomatology of schizophrenia and are compatible with the NMDAR hypofunction hypothesis of schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.